Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience.
Basara
N
N
Department of Bone Marrow Transplantation and Hematology/Oncology, Idar-Oberstein, Germany.
Kiehl
M G
MG
Blau
W
W
Römer
E
E
Bischoff
M
M
Schmetzer
B
B
Kirsten
D
D
Günzelmann
S
S
Fauser
A A
AA
D000208:Acute Disease; D000328:Adult; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002908:Chronic Disease; D016572:Cyclosporine / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007938:Leukemia / Q000401:mortality / Q000628:therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D009679:Nuclear Family; D012008:Recurrence; D012189:Retrospective Studies; D015996:Survival Rate; D014916:Whole-Body Irradiation
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid; D008727:Methotrexate